Effect of theophylline on urinary excretion of 3-methylhistidine in patients with lung disease
Metabolism, ISSN: 0026-0495, Vol: 40, Issue: 7, Page: 702-706
1991
- 1Citations
- 8Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Theophylline, which is commonly used for the treatment of lung disease, has been reported to stimulate lipolysis, glycogenolysis, and gluconeogenesis. This study was initiated to investigate whether theophylline therapy also induces catabolic changes in protein metabolism and thus provides additional substrates for energy metabolism. Urinary excretion of 3-methylhistidine (3-MH) as an index of myofibrillar protein catabolism was measured at the end of a 7-day treatment period with theophylline and a 5-day basal untreated control period in eight patients with stable chronic obstructive pulmonary disease (COPD), eight patients with stable asthma, and eight normal healthy volunteers. Basal urinary 3-MH excretion and 3-MH/creatinine ratios, and nutritional indices assessed were not different in the three groups. Under similar drug (except theophylline), dietary, and activity regimens, comparison of the two experimental periods showed that theophylline increased mean urinary 3-MH excretion and 3-MH/creatinine ratios in all three groups of subjects. These changes were significant in the COPD and asthmatic patients (mean 3-MH ± SD, μmol/d: basal, 176 ± 46 v 206 ± 46; and basal, 190 ± 27 v 216 ± 45, respectively, P <.05) and persisted when 3-MH values were normalized to creatinine excretion (15% to 38%, P <.005). In contrast, the mean increment was marginal in the group of normal volunteers and this discrepancy of effect between groups may be attributed to dietary noncompliance. Furthermore, the response of the COPD group was significantly greater than the asthmatic and control groups (1.8× and 11.3×, respectively, P <.05). In conclusion, these results suggest that theophylline may enhance myofibrillar protein degradation. This metabolic effect may be quantitatively significant during the therapeutic use of theophylline in COPD patients who are at risk for weight loss.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/002604959190087D; http://dx.doi.org/10.1016/0026-0495(91)90087-d; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0025743726&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/1870423; http://linkinghub.elsevier.com/retrieve/pii/002604959190087D; http://api.elsevier.com/content/article/PII:002604959190087D?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:002604959190087D?httpAccept=text/plain; https://linkinghub.elsevier.com/retrieve/pii/002604959190087D; http://dx.doi.org/10.1016/0026-0495%2891%2990087-d; https://dx.doi.org/10.1016/0026-0495%2891%2990087-d
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know